Xtandi (enzalutamide)

pCPA File Number: 22998

Negotiation Status:

Under consideration for negotiation

Indication(s):

For the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR)

Sponsor/Manufacturer:

Astellas Pharma Inc.

CDA-AMC Project Number:

PX0366-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable